AFT and RooLife launch OTC medicines online in China

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





7 July 2022

AFT and RooLife launch OTC medicines online in China
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) and RooLife Group (ASX: RLG) today
announce they have launched a range of AFT’s over the counter (OTC)
pharmaceuticals through their store on the China Cross Border E-Commerce (CBEC)
online platform Tmall Global. Further launches are to follow over the next few months.
The store, known as the ‘Kiwi Health Global Flagship Store’ was launched in 2020
initially with a trial range of AFT’s health supplements and has since achieved strong
support.
Now, following its registration under China’s CBEC OTC pilot scheme, which allows AFT
and RooLife to sell New Zealand registered medicines to Chinese consumers, the store
has become the first New Zealand direct-to-consumer OTC online medicine
marketplace on Tmall Global.
The store is now carrying AFT’s trusted portfolio of health and wellbeing products.
These include: Vitamin C Lipo Sachet, Vitamin D Lipo Sachet, Ferro Sachet, Kiwisoothe,
Crystawash Extend, Loraclear hay fever relief, and Histaclear non drowsy allergy relief.
As part of this two-phase launch, AFT will extend its OTC medical product portfolio,
which will include its patented Maxigesic pain relief medication and five additional
OTC medicine products.
The store is at the following link: https://kiwihealthbjp.tmall.hk

AFT Pharmaceuticals Founder and Managing Director Dr Hartley Atkinson said: “The
Kiwi Health Global Flagship Store offers a significant growth opportunity for AFT. We
are excited to be the first New Zealand company to be approved for the CBEC OTC
pilot scheme that launched in 2019.”
“T he Chinese market for OTC medicines is the world’s second largest behind the US
and is growing rapidly. In 2020 it was worth US$16.3 billion and it is now expected to
reach US$22.7 billion by 2023, as the Chinese population ages and becomes more
focussed on healthcare. Additionally, well over 58% of those sales occur online
1
.”
“The Kiwi Health Global Flagship Store aims to leverage the strong brand awareness
of AFT’s product range, the high regard and demand for New Zealand products in
China and the low numbers of OTC products approved on Tmall Global. “

1
www.azoyagroup.com/blog/view/the-e-commerce-opportunity-in-chinas-otc-pharmaceuticals-market/,
www.statista.com/outlook/cmo/otc-pharmaceuticals/china

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

“Our initial health supplements trial has already secured a strong following since its
launch, and we are delighted to reach more consumers in China with the launch of
our OTC range which will be rolled out in stages over the next few months. We also
believe the store will further assist us in amplifying our online presence in the world’s
largest e-commerce market.”
As China’s largest cross-border marketplace, Tmall Global is the premier channel
through which overseas brands and retailers can reach Chinese consumers, build
brand awareness, and gain valuable consumer insights in forming their overall China
strategy, without the need for physical operations in that country.
Pier Smulders, New Zealand Country Manager of Tmall Global’s owner Alibaba Group,
said: “We are delighted to see the Kiwi Health Tmall Global flagship store expand its
offering to now include OTC pharmaceutical products. This is an innovative step, and
we congratulate everyone involved and look forward to supporting their growth in
China.
“New Zealand products have a strong reputation and remain a popular choice with
Chinese consumers, who care more about their health and wellness than ever before.
The time is right for New Zealand brands to think about expanding their reach in
China.”
RooLife Managing Director, Bryan Carr added, "This partnership with AFT
Pharmaceuticals places us at the forefront of the market, directly servicing the strong
demand for international OTC pharmaceuticals from Chinese consumers.
RooLife provides the digital marketing, store operation and product distribution that
drives sales of AFT Pharmaceuticals products on the Tmall Global platform.
“The partnership leverages our China market and e-commerce expertise with AFT’s
extensive pharmaceutical experience and highly regarded product range,
presenting a fantastic opportunity for both our companies,” Mr Carr said.
Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief
Financial Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals (NZX:AFT, ASX:AFP)
www.aftpharm.com

AFT Pharmaceuticals are a growing multinational pharmaceutical company that
develops, markets, and distributes a broad portfolio of pharmaceutical products
across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over the counter, prescription, and hospital.
AFT Pharmaceutical's product portfolio comprises both proprietary and in -licensed
products, and includes patented, branded, and generic drugs.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com


About RooLife Group Ltd (ASX:RLG)
www.roolifegroup.com.au

The RooLife Group of companies provides fully integrated digital marketing and
customer acquisition services focusing on driving online sales of products and services
for its clients. With a key focus on driving sales in Australia and China the company’s
online e-Commerce marketplace assists businesses to sell directly to Chinese
consumers and accept payment via the Alipay mobile payments platforms. RooLife’s
key positioning is about knowing and remaining connected with Chinese consumers,
allowing brands to continually sell products to Chinese consumers based on their
profiles and purchasing behaviours.